Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | F13A1 | P00488 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12935941 | 0.86 | POLB (0.54) | EPHX1ALDH1A1MAPTKDM4EUSP2 | |
| SCHEMBL3837907 | 0.84 | CA12 (0.49) | ALDH1A1KDM4ELMNAPOLBSMN1; SMN2 | |
| SCHEMBL14141265 | 0.82 | NPC1 (0.59) | ALDH1A1MAPTKDM4EPOLBRAB9A | |
| SCHEMBL1094537 | 0.82 | CNR1 (0.57) | MAPTLMNAL3MBTL1RAB9ASMN1; SMN2 | |
| SCHEMBL4700346 | 0.82 | ESRRG (0.54) | ALDH1A1KDM4EPOLBSMN1; SMN2F13A1 | |
| SCHEMBL12964200 | 0.82 | EPHX1 (0.50) | EPHX1ALDH1A1MAPTKDM4EUSP2 | |
| SCHEMBL3833704 | 0.82 | MLYCD (0.46) | ALDH1A1KDM4ELMNAPOLBRAB9A | |
| Hydrochloric Acid SCHEMBL7334449 | 0.81 | ESRRG (0.52) | ALDH1A1KDM4EPOLBSMN1; SMN2F13A1 | |
| SCHEMBL14441217 | 0.80 | KDM4E (0.66) | EPHX1ALDH1A1MAPTKDM4EUSP2 | |
| SCHEMBL6433557 | 0.80 | KDM4E (0.61) | ALDH1A1MAPTKDM4EPOLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589126-B2 | 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-09-15 | — | — | US | disclosed |
| US-7563822-B2 | Agents for the prevention or treatment of renal diseases | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-07-21 | — | — | US | disclosed |
| EP-1331221-B1 | 5-AMIDINO-2-HYDROXYBENZENESULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES FOR THEIR PREPARATION | KISSEI PHARMACEUTICAL (JP) | 2009-01-14 | — | — | EP | disclosed |
| US-7217832-B2 | 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20070105829-A1 | 5-AMIDINO-2-HYDROXYBENZENESULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES FOR THEIR PREPARATION | Kissei Pharmaceutical Co.,Ltd. | 2007-05-10 | — | — | US | disclosed |
| US-7208524-B2 | 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-04-24 | — | — | US | disclosed |
| US-20060205812-A1 | 5-Amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation | KISSEI PHARMACEUTICAL CO., LTD. | 2006-09-14 | — | — | US | disclosed |
| US-20060116361-A1 | 5-Amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-06-01 | — | — | US | disclosed |
| US-20050107354-A1 | active ingredient a 5-amidino-2-hydroxybenzenesulfonamide derivative or a pharmaceutical acceptable salt thereof; excellent inhibitory effect on mesangial cell proliferation and decreasing effect on urine protein excretion | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2005-05-19 | — | — | US | disclosed |
| EP-1331221-A1 | 5-AMIDINO-2-HYDROXYBENZENESULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES FOR THEIR PREPARATION | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107354-A1 | active ingredient a 5-amidino-2-hydroxybenzenesulfonamide derivative or a pharmaceutical acceptable salt thereof; excellent inhibitory effect on mesangial cell proliferation and decreasing effect on urine protein excretion | REN, GLS, GRB2 | EPHX1 4602/4885ALDH1A1 3621/4885MAPT 4041/4885 |
| US-20060205812-A1 | 5-Amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation | F12, F2, F5 | EPHX1 1070/4885ALDH1A1 3234/4885MAPT 4699/4885 |
| US-20060116361-A1 | 5-Amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation | F12, F2, F5 | EPHX1 1070/4885ALDH1A1 3234/4885MAPT 4699/4885 |
| US-20070105829-A1 | 5-AMIDINO-2-HYDROXYBENZENESULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES FOR THEIR PREPARATION | F12, F2, F5 | EPHX1 1070/4885ALDH1A1 3234/4885MAPT 4699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.